Cited by 1,309Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Open access

Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice·2014·The Lancet

DOI 10.1016/s0140-6736(14)60845-x

Open this paper in CoChat — free account

Abstract

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60845-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citation
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948

Show all 35 references

Research works printed but not linked: 1

Wilke, 2014, J Clin Oncol, 32

Sorted by citations

Items 801–900 of 1,001

Assurance methods for designing a clinical trial with a delayed treatment effect
Salsbury, J. A., Oakley, J. E., Julious, S., & Hampson, L. V. (2023) · Statistics in Medicine · doi:10.1002/sim.10136 · Cited by 9
Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLC
Lee, A. T., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s492126 · Cited by 5
Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung Cancer
Arbour, K. C., Punekar, S. R., Luo, J., Johnson, M., Spira, A. I., Herzberg, B., Starodub, A., Sommerhalder, D., Hecht, J. R., Garrido‐Laguna, I., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2504059 · Cited by 5
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study
Neal, J. W., Santoro, A., González‐Cao, M., Lim, F. L., Fang, B. S., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Proto, C., Patel, S. B., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100666 · Cited by 5
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)
Kawachi, H., Tamiya, M., Oya, Y., Saito, G., Taniguchi, Y., Matsumoto, H., Sato, Y., Otsuki, T., Suzuki, H., Fukuda, Y., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.07.014 · Cited by 5
Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine
Dinić, J., Stojanov, S. J., Dragoj, M., Grozdanić, M., Podolski-Renić, A., & Pešić, M. (2024) · Life · doi:10.3390/life14091142 · Cited by 6
S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Tsao, A. S., Hsieh, M.-H., Koczywas, M., Tu, J. C., Riess, J. W., Tanvetyanon, T., Ma, B. T., Zhao, Y., Redman, M. W., Edelman, M. J., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100738 · Cited by 5
The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis
Zheng, Y., Chen, L., Liu, X., Li, R., Lei, H.-B., & Chen, G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428307 · Cited by 5
Taxane-Associated Acute Pain Syndrome: a Review of its Features and Management
Saito, Y. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01302-y · Cited by 5
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients
Tanaka, M., Hattori, Y., Ishii, T., Tohnai, R., Itoh, S., Kawa, Y., Kono, Y., Urata, Y., & Satouchi, M. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2019.12.008 · Cited by 5
Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer
Palumbo, G., Esposito, G., Carillio, G., Manzo, A., Montanino, A., Sforza, V., Costanzo, R., Sandomenico, C., Manna, C. L., Martucci, N., et al. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00008 · Cited by 5
Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer
Okuyama, H., Kagawa, Y., Masuishi, T., Mishima, S., Shirasu, H., Ando, K., Yuki, S., Muro, K., Yoshino, T., Yamazaki, K., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02004-9 · Cited by 5
[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer in the Elderly (2022 Edition)].
(2022) · PubMed · doi:10.3779/j.issn.1009-3419.2022.101.25 · Cited by 5
Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
Kareff, S. A., Gawri, K., Khan, K., Kwon, D., Rodríguez, E., Lopes, G. D. L., Jr., & Dawar, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1012783 · Cited by 5
Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment
Takahara, Y., Abe, R., Nagae, S., Tanaka, T., Ishige, Y., Shionoya, I., Yamamura, K., Nishiki, K., Nojiri, M., Kato, R., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15161 · Cited by 5
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study
Ren, S., Xiong, A., Yu, J. H., Wang, X., Han, B., Pan, Y., Zhao, J., Cheng, Y., Hu, S., Liu, T., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03715-4 · Cited by 7
Analytical and Clinical Validation of the Oncomine Dx Target Test to Assess HER2 Mutation Status in Tumor Tissue Samples From Patients With Non–Small Cell Lung Cancer Treated With Trastuzumab Deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 Studies
Qi, Z., Ha, T., Feng, W., Karnoub, M., Pereira, K., Shiga, R., Smit, E. F., Goto, Y., Langen, A. J. D., Goto, K., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2024-0014-oa · Cited by 5
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer.
Horinouchi, H. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.06.08 · Cited by 5
Promising Targets and Current Clinical Trials in Metastatic Squamous Cell Lung Cancer
Vincent, M. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00320 · Cited by 6
The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.
Tan, W. L., & Ng, Q. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.10.12 · Cited by 5
Afatinib en pacientes con carcinoma escamoso de pulmón: contexto actual y opción de un tratamiento oral
Cobo, M., Gutiérrez, V., Rodelo, L., López, O., Ruiz, M. P., & Godoy-Ortíz, A. (2016) · Medicina Clínica · doi:10.1016/s0025-7753(16)30260-3 · Cited by 5
Ramucirumab: a Novel Anti-Angiogenic Agent in the Treatment of Metastatic Colorectal Cancer
Goel, G., Chauhan, A., & Hosein, P. J. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0329-2 · Cited by 5
Cardiotoxicity of Anticancer Therapies
Said, R., Nickolich, M. S., Lenihan, D. J., & Tsimberidou, A. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-43096-6_2 · Cited by 5
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives
Tiefenbacher, A., & Pirker, R. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0408-y · Cited by 5
The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer
Khetpal, N., Ali, S., Kumar, R., Rashid, M., & Ahmad, S. (2018) · Springer eBooks · doi:10.1007/978-981-13-1486-5_3 · Cited by 5
Management of Toxicities of Targeted Therapies
Yang, J. C., Lin, C.-C., & Chu, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00049-4 · Cited by 4
[Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].
Zheng, X., Wang, H., Zhang, G., Yan, X., & Ma, Z. (2018) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2018.07.02 · Cited by 5
Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
Liu, Y., Chen, T., Shen, D., Zhang, W., Wang, C.-G., Jiang, J., & Zeng, D. (2019) · Journal of International Medical Research · doi:10.1177/0300060519887276 · Cited by 5
Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer
Kito, Y., Satake, H., Taniguchi, H., Yamada, T., Horie, Y., Esaki, T., Denda, T., Yasui, H., Izawa, N., Masuishi, T., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04116-x · Cited by 5
Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC
Hu, R., Li, T., Hui, K., Chen, Z., Wang, N., Wu, X., Ge, L., & Zhou, L. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11492 · Cited by 5
Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States
Hess, L. M., Cui, Z. L., Li, X. I., Molife, C., & Oton, A. B. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1866516 · Cited by 5
Phase 1 dose-escalation study of apatinib and irinotecan in esophageal squamous cell carcinoma patients
Jia, J., Yu, J., Sun, Z., Yang, Y., Liu, C., Xiao, Y., & Zhang, X. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2492 · Cited by 5
[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].
Zhou, J., & Chen, J. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.16 · Cited by 5
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer
Aggarwal, H., Ndirangu, K., Winfree, K. B., Muehlenbein, C. E., Zhu, E., Tongbram, V., & Thom, H. H. Z. (2023) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0016 · Cited by 5
The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer
Díaz-Serrano, A., Martínez, M. C. R., & García‐Carbonero, R. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1182430 · Cited by 5
Immunotherapeutic Approaches in Cancer
Keshavarz‐Fathi, M., & Rezaei, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814039-0.00002-3 · Cited by 6
A multi-center, Phase II trial of nab-paclitaxel and gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
TACHIHARA, M. Y., Kiriu, T., Hata, A., Hatakeyama, Y., Nakata, K., Nagano, T., Yamamoto, M., Kobayashi, K., Ohnishi, H., Katakami, N., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s208224 · Cited by 5
Systemic therapy for elderly patients with non–small cell lung cancer: Where do we stand in 2019?
Aggarwal, C., & Langer, C. J. (2020) · Cancer · doi:10.1002/cncr.32625 · Cited by 5
A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy
Wang, C., Chiu, L., Tung, P., Kuo, C. S., Chu, C., Huang, A. C., Wang, C., Chen, C., Yang, C., & Hsu, P. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00152-6 · Cited by 5
Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer
Cooper, M. R., Binkowski, C., Hartung, J., & Towle, J. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s80239 · Cited by 5
Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review
Li, X., Zhang, D., Guan, S., Ye, W., Liu, L., & Lou, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21452 · Cited by 5
Necitumumab: a new option for first-line treatment of squamous cell lung cancer
Aguilar, E. J., Fraile, J. Z., & Rodríguez, L. P.-A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1498839 · Cited by 5
Elusive Target of Angiogenesis in Small-Cell Lung Cancer
Neal, J. W., & Wakelee, H. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6084 · Cited by 5
Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System
Kelner, M., da Silva, B. C., Montella, T. C., Aguiar, P. N., Lopes, G. D. L., Jr., Ferreira, C. G., & Marchi, P. D. (2022) · Value in Health Regional Issues · doi:10.1016/j.vhri.2022.08.004 · Cited by 4
CD52 knockdown inhibits aerobic glycolysis and malignant behavior of NSCLC cells through AKT signaling pathway
Cai, Y., Zhao, J., Luo, C. H., Fang, M., Yi, Y., Chen, Y., Huang, P., Liao, L., & Huang, L. (2024) · Journal of Cancer · doi:10.7150/jca.86511 · Cited by 4
Respiratory microbiota diversity as a predictive biomarker for the efficacy of PD‑1 blockades in patients with advanced non‑small cell lung cancer: A retrospective exploratory study
Zhang, L., Li, M., Li, X., Yang, B., Xiao, T., Wang, P., & Zhang, W. (2025) · Oncology Letters · doi:10.3892/ol.2025.14997 · Cited by 4
Safety Evaluation of SH003 and Docetaxel Combination in Patients With Breast and Lung Cancer: A Multi-Center, Open-Label, Dose Escalation Phase I Clinical Trial
Cheon, C., Kim, H., Kang, S. Y., Lee, S. Y., Park, K. H., & Ko, S. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354251363892 · Cited by 4
Self-citation
Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial
Krug, S., Kegel, T., Gress, T. M., Rinke, A., Apostolidis, L., Jann, H., König, A. O., Hörsch, D., Schrader, J., Ettrich, T. J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08900-7 · Cited by 4
Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer
Kenmotsu, H., Mori, K. P., Mizuno, R., Mamesaya, N., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., Naito, T., Murakami, H., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.12.011 · Cited by 4
Expression of KAI1 and AGR2 in lung adenocarcinoma and their clinicopathological significance
Ci, H., & Wu, L. (2022) · Medicine · doi:10.1097/md.0000000000032498 · Cited by 4
Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer
Akagi, K., Yagishita, S., Ohuchi, M., Hayashi, Y., Takeyasu, Y., Masuda, K., Shinno, Y., Okuma, Y., Yoshida, T., Goto, Y., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.03.001 · Cited by 4
Influence of background cardiovascular risk factors on VEGF inhibitor-related adverse vascular events in patients with non-small cell lung cancer: a retrospective study
Naito, T., Minegishi, Y., Shiraishi, H., Hoshino, T., Maeda, J., Yokota, T., Ikeda, S., Miyanaga, A., & Seike, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05092-4 · Cited by 4
Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study)
Okuma, Y., Nomura, S., Ninomiya, K., Gyotoku, H., Murakami, S., Kogure, Y., Harada, D., Okishio, K., Okamoto, H., & Goto, Y. (2023) · Future Oncology · doi:10.2217/fon-2022-1128 · Cited by 4
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
Onoi, K., Yamada, T., Morimoto, K., Kawachi, H., Tsutsumi, R., Takeda, T., Okada, A., Tamiya, N., Chihara, Y., Shiotsu, S., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01045-0 · Cited by 4
Long-term progression-free survival in non-small cell lung cancer patients: a spotlight on bevacizumab and its biosimilars
Seiwerth, F., Bitar, L., Samaržija, M., & Jakopović, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2405562 · Cited by 4
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
Liu, Y.-Y., Tsai, M.-Y., Liu, T., Liu, Y., Lin, Y., Yeh, C.-H., Lin, Y.-C., & Chen, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-13066-z · Cited by 4
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Mangal, S., Debnath, A., Mazumder, R., Mazumder, A., Singh, R. K., Sanchitra, J., Jan, S., Pandey, P., Kumar, B., & Singh, A. K. (2024) · All Life · doi:10.1080/26895293.2024.2417192 · Cited by 4
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for ramucirumab
Lin, L., Zheng, X., Wu, M., Chen, Y., Nian, Q., Lin, Y., & Chen, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2441286 · Cited by 4
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair, P., Joos, L., Warschkow, R., Dutly, A., Ess, S. M., Hitz, F., Früh, M., Brutsche, M. H., Baty, F., Krähenbühl, S., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.027 · Cited by 4
Ramucirumab for the treatment of advanced or metastatic non-small cell lung cancer
Takeda, K., & Daga, H. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1248397 · Cited by 4
Imaging of Novel Oncologic Treatments in Lung Cancer Part 1
Halpenny, D. F., O’Dwyer, E., Girshman, J., & Ginsberg, M. S. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000451 · Cited by 4
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
Morgensztern, D., Cobo, M., Ponce-Aix, S., Postmus, P. E., Bennouna, J., Fischer, J. R., Juan, Ó., Stewart, D. J., Ardizzoni, A., Bhore, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.569715 · Cited by 4
Self-citation
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases
Kaneda, H., Sawa, K., Daga, H., Okada, A., Nakatani, Y., Atagi, S., Okishio, K., Tani, Y., Matsumoto, Y., Ogawa, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01147-w · Cited by 4
Lung Adenocarcinoma
Patel, B. A., & Liu, S. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00006-7 · Cited by 4
Therapeutic Antibodies and Immunologic Conjugates
Dobrenkov, K., & Cheung, N. V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00030-x · Cited by 4
Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer
Si, J.-F., Xiang, J., Wei, J., Hao, Y., & Song, Z. (2022) · Neoplasma · doi:10.4149/neo_2022_220329n348 · Cited by 4
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
Rothschild, S. I. (2014) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s49490 · Cited by 4
Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
Chen, J., Chen, J., Wu, X., Shi, T., & Kang, M.-L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100618 · Cited by 4
Economics of ramucirumab for metastatic colorectal cancer
Zeichner, S. B., Kohn, C. G., & Goldstein, D. A. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2016.1259070 · Cited by 4
Molecular Diagnosis and Targeting for Lung Cancer
Yoneda, K., & Tanaka, F. (2017) · Current human cell research and applications · doi:10.1007/978-981-10-6469-2_1 · Cited by 4
Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Kotake, M., Kuwako, T., Imai, H., Tomizawa, Y., Kaira, K., Yoshii, A., Ochiai, M., Miura, Y., Osaki, T., Sakurai, R., et al. (2020) · Chemotherapy · doi:10.1159/000508715 · Cited by 4
Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non–Small Cell Lung Cancer
Yoshimura, N., Sawa, K., Nakai, T., Matsumoto, Y., Mitsuoka, S., Kimura, T., Asai, K., Yana, T., Kawaguchi, T., & Hirata, K. (2021) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000876 · Cited by 4
Safety and effectiveness of ramucirumab and docetaxel: a single-arm, prospective, multicenter, non-interventional, observational, post-marketing safety study of NSCLC in Japan
Chen, Y., Nagaoka, S., Katayose, T., & Sekine, N. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2023127 · Cited by 4
Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study
Zhao, J., Cheng, Y., He, L., Wang, J., Xi, Q., & Gong, C. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1292 · Cited by 3
Pathways and cost-effectiveness of routine lung cancer inpatient care in rural Anhui, China: a retrospective cohort study protocol
Shen, X., Diao, M., Lu, M., Feng, R., Zhang, P., Jiang, T., & Wang, D. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018519 · Cited by 4
Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
Nishimoto, K., Karayama, M., Inui, N., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Nakamura, Y., et al. (2018) · Medical Oncology · doi:10.1007/s12032-018-1172-x · Cited by 4
Impact of EMT in stage�IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
Villalobos, M., Czapiewski, P., Reinmuth, N., Fischer, J. X. F. R., Andreas, S., Kortsik, C., Serke, M. H., Wolf, M., Neuser, P., Reuß, A., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10153 · Cited by 4
Self-citation
The lesson learned from figitumumab clinical program and the hope for better results in squamous lung cancer.
Maïo, M. D., & Scagliotti, G. V. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2015.01.02 · Cited by 4
NICE guidance on ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Hall, C. J., Umeweni, N., Knight, H. P., & Smith, L. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30435-1 · Cited by 4
KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer
Horinouchi, H. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.135 · Cited by 4
Inhibition of non-homologous end joining mitigates paclitaxel resistance resulting from mitotic slippage in non-small cell lung cancer
Tsuji, K., Kikuchi, E., Takashima, Y., Shoji, T., Takahashi, H., Ito, S., Morinaga, D., Kashima, M., Maeda, M., Kitai, H., et al. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2243761 · Cited by 3
Chinese Herbal Compound Xiaoliu Pingyi Recipe Inhibits the Growth of Lung Adenocarcinoma by Regulating the Tumor Vascular Microenvironment
Yang, F., Li, H., Hu, X., Fu, R., Li, X., & Li, H. (2024) · Integrative Cancer Therapies · doi:10.1177/15347354241273962 · Cited by 3
In Silico‐Designed G‐Quadruplex Targeting Peptide Attenuates VEGF‐A Expression, Preventing Angiogenesis in Cancer Cells
Banerjee, N., Roy, L., Panda, S., Roychowdhury, T., & Chatterjee, S. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70018 · Cited by 4
Anlotinib in cancer therapy: mechanisms of action, clinical applications, and future perspectives
Ding, J., Yeong, C. H., Wang, L., Shi, C., Li, L., Song, L., Ma, W., & Li, P. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-025-04811-7 · Cited by 3
Antibody–drug conjugates versus docetaxel for previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Khan, S. R., Eiras, L. M., Boldt, G., Raphael, J., & Breadner, D. A. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251387393 · Cited by 3
A tumor spheroid array chip for high-fidelity evaluation of liposomal drug delivery through the EPR effect
Lee, Y., Kim, S., Koh, H., Park, Y., Han, J. Y., & Ko, J. (2025) · Lab on a Chip · doi:10.1039/d5lc00893j · Cited by 3
Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis
Nishizaki, M., & Shibutani, Y. (2026) · Hypertension Research · doi:10.1038/s41440-025-02513-4 · Cited by 3
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)
Kaneda, H., TACHIHARA, M. Y., Toi, Y., Kuyama, S., Ichihara, E., Fujisaka, Y., Azuma, K., Kurata, T., Kubo, A., Tanaka, H., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109432 · Cited by 3
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors
Melero, I., de Miguel, M., Garralda, E., de Velasco, G., Joerger, M., Martín-Liberal, J., Reig, M., König, D., Trojan, J., Goebeler, M.-E., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01818-2 · Cited by 3
Self-citation
[Current Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted Therapy].
Zhang, G., Wang, H., Zhang, M., Li, P., & Ma, Z. (2015) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2015.09.10 · Cited by 3
Management of Metastatic Nonsmall Cell Lung Cancer in Elderly
Sheth, H., Kumar, P., & Limaye, S. A. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732784 · Cited by 3
Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials
Tang, L., Wang, T., Zhang, Q., Yu, S., Li, W., Yao, S., & Cheng, H. (2022) · Journal of Oncology · doi:10.1155/2022/2476469 · Cited by 3
Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment
Li, S., Zhang, M., Liu, J. H., Liu, S., Zhu, C., Shang, D., Guan, Y., & Wang, Q. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100962 · Cited by 4
Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy
Qin, K., Wang, K., Li, S., Hong, L., Padmakumar, P., Rinsurongkawong, W., Hubert, S. M., Le, X., Vokes, N. I., Rai, K., et al. (2024) · Cancers · doi:10.3390/cancers16050935 · Cited by 4
Modelling the Effectiveness of Tepotinib in Comparison to Standard-of-Care Treatments in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring METex14 Skipping in the UK
Batteson, R., Hook, E. S., Wheat, H., Hatswell, A. J., Vioix, H., McLean, T., Alexopoulos, S. T., Baijal, S., & Paik, P. K. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01038-z · Cited by 3
Phase II study of ramucirumab and docetaxel for previously platinum-treated patients with non-small cell lung cancer and malignant pleural effusion (PLEURAM study)
Takemoto, S., Fukuda, M., Ogata, R., Senju, H., Sugasaki, N., Nakatomi, K., Tomono, H., Suyama, T., Sasaki, E., Matsuo, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-508 · Cited by 3
KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
Eser, M., Hekimoğlu, G., Yarar, M. H., Canbek, S., & Özçelik, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-75208-4 · Cited by 3
The impact of histological types on the efficacy of angiogenesis inhibitors in the treatment of advanced NSCLC: a meta-analysis of randomized controlled trials
Gu, L., Zhang, J., Liu, J., Chen, H., Wu, W., Li, X., Wu, Y., & Zhang, K. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s90407 · Cited by 3
Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer
Garzotto, A. A. R., Díaz-García, C. V., Agudo-López, A., Prieto‐García, E., Ponce, S., Lopez-Martin, J. A., Paz-Ares, L. G., Iglesias, L., & Agulló-Ortuño, M. T. (2016) · Medical Oncology · doi:10.1007/s12032-016-0824-y · Cited by 3
From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?
D’Argento, E., Rossi, S., Schinzari, G., Strippoli, A., Basso, M., Cassano, A., & Barone, C. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0437-x · Cited by 3

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Self-citation
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Czyżewicz, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba8006 · Cited by 17
Self-citation
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash, K., Doval, D. C., Rangarajan, B., Somani, N., Pruthi, A., Dyachkova, Y., & Puri, T. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_159_21 · Cited by 3
Self-citation
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A. G., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L. G., Pérol, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv343.04 · Cited by 2
Self-citation

See all

Authors: Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
Affiliations: University of California, Los Angeles (US)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Instituto Nacional de Cancerología (MX)
Tata Memorial Hospital (IN)
Sotiria General Hospital (GR)
Samsung Medical Center (KR)
Russian Cancer Research Center NN Blokhin (RU)
Charing Cross Hospital (GB)
University Hospital Heidelberg (DE)
Azienda Ospedaliera San Gerardo (IT)
Cancer Center of Kansas (US)
Gemeinschaftskrankenhaus Herdecke (DE)
Yonsei University Health System (KR)
Institutul Oncologic Bucuresti (RO)
City Clinical Oncology Center (RU)
German Center for Lung Research (DE)
Ospedale di Livorno (IT)
Eli Lilly (United States) (US)
Corresponding author: Garon, Edward B
ORCID: Garon, Edward B
Ciuleanu, Tudor-Eliade
Arrieta, Oscar
Prabhash, Kumar
Park, Keunchil
Gorbunova, Vera
Pikiel, Joanna
Thomas, Michael
Dakhil, Shaker
Kim, Joo-Hang
Grigorescu, Alexandru
Reck, Martin
Cappuzzo, Federico
Sashegyi, Andreas
Yurasov, Sergey
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-08
Volume: 384
Issue: 9944
Pages: 665-673
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)60845-x
OpenAlex: W2140980839
Cited by: 1,309
References: 35
Citations by year: 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
FWCI: 116.89
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
MeSH terms: Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks